Photo of Talha Badar from mayoclinic.org
Jun 15, 2024, 07:20
Talha Badar: Optimization of venetoclax based therapy
Talha Badar, Assistant Professor at Mayo Clinic Comprehensive Cancer Center shared on X:
“Wei: Optimization of venetoclax based therapy.
1) use hydrea or flat dose cytarabine to bring WBC below 25k before initiation of Venetoclax.
2) BM biopsy at D21.
3) G-CSF to reduce neutropenic nadir if D21 BM shows blast clearance.
4) MRD clearance may take upto 8 cycles, so continue Ven based regimen if patient is having response.
5) triplet therapy with FLT3i, menin inhibitors etc can reduce risk of Ven resistance.”
Source: Talha Badar/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 13:46
Dec 21, 2024, 13:40
Dec 21, 2024, 13:33
Dec 21, 2024, 13:20
Dec 21, 2024, 13:12